A Phase 3 interventional study of Optimized Medical Treatment and Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease, sponsored by AbbVie. Completed at 38 sites in 9 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2023-11-28.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing levodopa in Parkinson Disease — 3 open to participants now, 3 under way, none of them phase 3. Levodopa · Parkinson Disease.
Among the 51 studies testing levodopa in Parkinson Disease, this one is the 18th largest by enrollment of the 50 interventional ones that give a count, is one of 4 that started in 2015, is one of 12 in phase 3, and was the 38th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →3 of the 51 studies testing levodopa in Parkinson Disease are open now, in 2 countries. Recruiting first, the newest first:
Second Affiliated Hospital of Soochow University · Sites in China
Ages 30–80
Emory University · Sites in United States
Ages 45–75 · Healthy volunteers
Beth Israel Deaconess Medical Center · Sites in United States
By country, each count listing its studies:
Levodopa: first FDA approval 1970 (LARODOPA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 11 · Phase 3 12 · Phase 4 17
First in 1998; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 89 is above the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 56 across the 50 interventional studies. Of the 45 that completed or were terminated, 18 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 51 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
44 studies in Parkinson Disease by AbbVie: 6 open now, 9 under way, none of them phase 3. Of 33 finished, 18 (55%) have results posted.
Among the 44 studies in Parkinson Disease by AbbVie, this one is the 11th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2015, is one of 16 in phase 3, and was the 15th registered.
AbbVie’s Parkinson Disease studies by the year they started, since 2006.
1 of the studies testing levodopa in Parkinson Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06234995Emory UniversityCortical Electrophysiology of Response Inhibition in Parkinson's Disease | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 51 studies testing levodopa in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 44 in Parkinson Disease:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to examine the effect of LCIG relative to that of OMT on NMS associated with PD.
The study will consist of 3 sequential parts:
Part 1: Screening period. The screening period will consist of 3 visits, Visit 1 (V1), Visit 2 ([V2] [optional]) and the Randomization Visit (V3) in which the participant will be assessed to determine eligibility. The duration of the Screening Period can be between 30 to 67 days to accommodate the required procedures, training and collection of diaries, and to allow for stabilization of anti-PD medications and medications to treat NMS. All anti-PD medications and medications to treat NMS are required to be stable for a minimum of 30 days prior to randomization.
Part 2: Treatment period. Those participants randomized to OMT at the end of V3 will remain on their current optimized regimen. The day after randomization will be considered Day 1 of their treatment period and participants will have study visits at the end of Weeks 2, 6, 12, and 26. All participants randomized to the LCIG group should have all anti-PD medications, with the exception of levodopa formulations, tapered off within 14 days after randomization. Optional nasojujunal (NJ) and/or percutaneous endoscopic gastrostomy with a jejunal tube (PEG-J) placement will then occur. After that, the participant may begin initiation and titration of LCIG infusion to be adjusted to obtain the optimal clinical response. The day of initial NJ or PEG-J placement will be considered Day 1 for participants in the LCIG group. Study visits happen at the end of Weeks 2, 6, 12, and 26.
Part 3: Extension/Transition Period. Eligible participants who complete the 26 week study may continue into the Extension Period of the study. Participants in the LCIG arm will have study drug dispensation every 4 weeks and will have study visits every 6 months. Participants from the OMT arm will undergo the NJ (optional) and PEG-J procedures, titration, plus have visits at 2 weeks, 6 weeks, 3 months and 6 months post NJ or PEG-J. Participants will then continue to receive study drug every 4 weeks and will have study visits every 6 months until Duodopa is commercially available. Transition to a Post-Trial Access protocol will be possible if Duodopa does not become commercially available in a location.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to continue OMT remain on their current optimized regimen. During the 26-week treatment phase, changes to anti-PD and NMS medications are to remain stable and can only be made if medically indicated. Eligible participants may elect to enter an extension/transition follow-up period to receive an individually optimized LCIG dose (after NJ and/or PEG-J placement), in order to transition to commercially available LCIG.
Drug: Optimized Medical Treatment · Drug: Levodopa-Carbidopa Intestinal Gel · Device: Nasojejunal (NJ) tube · Device: Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube
Participants randomized to LCIG at an individually optimized dose (after NJ and/or PEG-J placement), in accordance with the LCIG approved product label for countries participating in the study. During the 26-week treatment phase, changes to anti-PD and NMS medications are to remain stable and can only be made if medically indicated. The total daily dose of LCIG was composed of 3 components: (i) the morning dose, (ii) continuous maintenance infusion dose and (iii) extra doses. The continuous infusion is expected to run over a period of 16 consecutive hours each day. Eligible participants may elect to enter an extension/transition follow-up period to receive an individually optimized LCIG dose, in order to transition to commercially available LCIG.
Drug: Levodopa-Carbidopa Intestinal Gel · Device: Nasojejunal (NJ) tube · Device: Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube
Oral, sublingual or transdermal anti-PD medications and medications to treat NMS per Investigator discretion and/or in accordance with approved product label of the prescribed medications.
Drug pages: Levodopa · Carbidopa
Also known as: ABT-SLV187, Duodopa, LCIG
optional prior to PEG-J placement
Change From Baseline to Week 26 in the NMSS Total Score
The NMSS consists of 30 questions in 9 domains (cardiovascular/falls, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, GI tract, urinary, sexual function, miscellaneous). Score of each question is calculated by multiplying severity\*frequency. Severity and frequency are rated using a scale ranging from 0 (none) to 3 (severe) for severity and from 1 (rarely) to 4 (very frequent) for frequency. Total score is the sum of 9 domains, and ranges from 0 to 360, with a lower value indicating a more desirable outcome. Repeated-measure analysis.
Time frame: Baseline, Week 26
Change From Baseline to Week 26 in the Modified PDSS-2 Total Score
The PDSS-2 addresses PD-specific sleep disturbances such as restless leg syndrome (RLS), morning akinesia, pain, and sleep apnea. The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 \[never\] to 4 \[very often\]). Scores are calculated for each of the 3 domains (motor symptoms at night, PD symptoms at night, and disturbed sleep) as well as a total score. The PDSS-2 domain scores range from 0 to 20 and the total score is a sum of the 3 domains and ranges from 0 to 60. Repeated measure analysis.
Time frame: Baseline, Week 26
Change From Baseline to Week 26 in Parkinson's Disease Questionnaire (PDQ-8) Summary Index Score
The PDQ-8 is a disease-specific instrument designed to measure aspects of health relevant to PD. Eight questions including the mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort are assessed on a 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Summary index score is the sum of each question divided by 32 and multiplied by 100. Scores range from 0 to 100 with lower values desirable.
Time frame: Baseline, Week 26
Clinical Global Impression of Change (CGI-C) Final Score
CGI-C score is a clinician's impression of a subject's change in status on a 7-point scale (1 = very much improved, 2 = much improved, 3 = minimally Improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse). Scores range from 1 to 7, with lower score desirable.
Time frame: End of Treatment Period (up to Week 26)
Change From Baseline at Week 26 in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score
UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease of 42 total questions. Part I (Questions 1 - 4), Part II (Questions 5 - 17), Part III (Questions 18 - 31), and Part IV (Questions 32 - 42). Questions 35 - 38 and 40 - 42 are 2-point (0 and 1), all other questions are 5-point (0 - 4). Part II scores range from 0 to 52 with lower value desirable.
Time frame: Baseline, Week 26
Change From Baseline to Week 26 in the NMSS Domain Scores
The NMSS consists of 30 questions in 9 domains. Score of each question is calculated by multiplying severity\*frequency. Severity and frequency are rated using a scale ranging from 0 (none) to 3 (severe) for severity and from 1 (rarely) to 4 (very frequent) for frequency. Cardiovascular/falls scores range from 0 - 24 with lower value desirable. Sleep/fatigue scores range from 0 - 48 with lower value desirable. Mood/cognition scores range from 0 - 72 with lower value desirable. Perceptual problems/hallucinations scores range from 0 - 36 with lower value desirable. Attention/memory scores range from 0 - 36 with lower value desirable. Gastrointestinal tract scores range from 0 - 36 with lower value desirable. Urinary scores range from 0 - 36 with lower value desirable. Sexual function scores range from 0 - 24 with lower value desirable. Miscellaneous scores range from 0 - 48 with lower value desirable. Repeated-measure analysis.
Time frame: Baseline, Week 26
Change From Baseline to Week 26 in the Modified PDSS-2 Domain Scores
The PDSS-2 addresses PD-specific sleep disturbances such as restless leg syndrome (RLS), morning akinesia, pain, and sleep apnea. The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 \[never\] to 4 \[very often\]). Scores are calculated for each of the 3 domains (motor symptoms at night, PD symptoms at night, and disturbed sleep) as well as a total score. The PDSS-2 domain scores range from 0 to 20 and the total score is a sum of the 3 domains and ranges from 0 to 60. Repeated measure analysis.
Time frame: Baseline, Week 26
Change From Baseline at Week 26 in UPDRS Parts I, III, and IV Score
UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease of 42 total questions. Part I (Questions 1 - 4), Part II (Questions 5 - 17), Part III (Questions 18 - 31), and Part IV (Questions 32 - 42). Questions 35 - 38 and 40 - 42 are 2-point (0 and 1), all other questions are 5-point (0 - 4). Part I is the sum of Questions 1 - 4; scores range from 0 to 16 with lower value desirable. Part III is the sum of Questions 18 - 31 (Questions 20 - 26 apply to multiple body parts, resulting in 27 answers total); scores range from 0 to 108 with lower value desirable. Part IV is the sum of Questions 32 - 42; scores range from 0 to 23 with lower value desirable.
Time frame: Baseline, Week 26
Change From Baseline at Week 26 in Parkinson's Anxiety Scale (PAS) Total Score
PAS is a 12-item scale developed specifically to measure severity in anxiety in Parkinson's disease for the following items: Feeling anxious or nervous; Feeling tense or stressed; Being unable to relax; Excessive worrying about everyday matters; Fear of something bad, or even the worst, happening; Panic or intense fear; Shortness of breath; Heart palpitations or heart beating fast; Fear of losing control; Social situations; Public settings; Specific objects or situations. Severity for each item is rated as: 0, Never; 1 Rarely; 2, Sometimes; 3, Often; 4, Nearly always. Total score is the sum of the12 item scores, with a range of 0 to 48; a lower value is desirable.
Time frame: Baseline, Week 26
Change From Baseline at Week 26 in Geriatric Depression Scale (GDS-15) Score
The GDS-15 is a short, self-report reliable and valid screening instrument for depression in the elderly of 15 yes/no questions: 1) Satisfied with life 2) Dropped many activities and interests 3) Life is empty 4) Often get bored 5) In good spirits most of the time 6) Afraid that something bad is going to happen 7) Feel happy most of the time 8) Often feel helpless 9) Prefer to stay at home, rather than going out and doing things 10) Feel that have more problems with memory than most 11) Think it is wonderful to be alive now 12) Feel worthless 13) Feel full of energy 14) Situation is hopeless 15) Most subjects are better off. Answers of 'yes' to questions 2, 3, 4, 6, 8, 9, 10, 12, 14, 15 are scored 1 point. Answers of 'no' to questions 1, 5, 7, 11, 13 are scored 1 point. The 15 items are summed and scores range from 0 - 15 with lower value desirable.
Time frame: Baseline, Week 26
Change From Baseline at Week 26 in King's PD Pain Scale (KPPS) Score
The KPPS score is a clinical PD-specific pain scale of 14 items addressing the following 7 domains: musculoskeletal pain, chronic pain, fluctuation-related pain, nocturnal pain, orofacial pain, neuropathic pain, radicular pain. Each domain item is scored by severity (0, none to 3, very severe) multiplied by frequency (0, never to 4, all the time) resulting in a subscore of 0 - 12 (with lower value desirable), the sum of the 14 items gives the total score with a range from 0 to 168 with lower value desirable.
Time frame: Baseline, Week 26
Patient Global Impression of Change (PGIC) Final Score
The PGIC is a 7-point response scale. The participant was asked by the Investigator or qualified designee to rate their change in status using the following 7-point scale: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. PGIC score ranges from 1 to 7 with lower score desirable.
Time frame: End of Treatment Period (up to Week 26)
This study was conducted at 32 sites in 9 countries.
| Milestone | Optimized Medical Treatment | LCIG |
|---|---|---|
| Started | 44 | 45 |
| Completed | 41 | 38 |
| Not completed | 3 | 7 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Milestone | Optimized Medical Treatment | LCIG |
|---|---|---|
| Started | 10 | 14 |
| Transitioned to commercial lcig | 5 | 7 |
| Completed | 5 | 10 |
| Not completed | 5 | 4 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Other, not specified | 4 | 2 |
The NMSS consists of 30 questions in 9 domains (cardiovascular/falls, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, GI tract, urinary, sexual function, miscellaneous). Score of each question is calculated by multiplying severity\*frequency. Severity and frequency are rated using a scale ranging from 0 (none) to 3 (severe) for severity and from 1 (rarely) to 4 (very frequent) for frequency. Total score is the sum of 9 domains, and ranges from 0 to 360, with a lower value indicating a more desirable outcome. Repeated-measure analysis.
| score on a scale | Optimized Medical Treatment | LCIG |
|---|---|---|
| Change From Baseline to Week 26 in the NMSS Total Score | -23.83 ± 8.30 | -32.04 ± 8.53 |
The PDSS-2 addresses PD-specific sleep disturbances such as restless leg syndrome (RLS), morning akinesia, pain, and sleep apnea. The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 \[never\] to 4 \[very often\]). Scores are calculated for each of the 3 domains (motor symptoms at night, PD symptoms at night, and disturbed sleep) as well as a total score. The PDSS-2 domain scores range from 0 to 20 and the total score is a sum of the 3 domains and ranges from 0 to 60. Repeated measure analysis.
| score on a scale | Optimized Medical Treatment | LCIG |
|---|---|---|
| Change From Baseline to Week 26 in the Modified PDSS-2 Total Score | -8.98 ± 2.00 | -7.41 ± 2.01 |
The PDQ-8 is a disease-specific instrument designed to measure aspects of health relevant to PD. Eight questions including the mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort are assessed on a 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Summary index score is the sum of each question divided by 32 and multiplied by 100. Scores range from 0 to 100 with lower values desirable.
| score on a scale | Optimized Medical Treatment | LCIG |
|---|---|---|
| Change From Baseline to Week 26 in Parkinson's Disease Questionnaire (PDQ-8) Summary Index Score | -1.75 ± 2.96 | -5.56 ± 2.97 |
CGI-C score is a clinician's impression of a subject's change in status on a 7-point scale (1 = very much improved, 2 = much improved, 3 = minimally Improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse). Scores range from 1 to 7, with lower score desirable.
| score on a scale | Optimized Medical Treatment | LCIG |
|---|---|---|
| Clinical Global Impression of Change (CGI-C) Final Score | 4.9 ± 0.25 | 2.5 ± 0.24 |
UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease of 42 total questions. Part I (Questions 1 - 4), Part II (Questions 5 - 17), Part III (Questions 18 - 31), and Part IV (Questions 32 - 42). Questions 35 - 38 and 40 - 42 are 2-point (0 and 1), all other questions are 5-point (0 - 4). Part II scores range from 0 to 52 with lower value desirable.
| score on a scale | Optimized Medical Treatment | LCIG |
|---|---|---|
| Change From Baseline at Week 26 in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score | 0.53 ± 0.89 | -2.26 ± 0.87 |
The NMSS consists of 30 questions in 9 domains. Score of each question is calculated by multiplying severity\*frequency. Severity and frequency are rated using a scale ranging from 0 (none) to 3 (severe) for severity and from 1 (rarely) to 4 (very frequent) for frequency. Cardiovascular/falls scores range from 0 - 24 with lower value desirable. Sleep/fatigue scores range from 0 - 48 with lower value desirable. Mood/cognition scores range from 0 - 72 with lower value desirable. Perceptual problems/hallucinations scores range from 0 - 36 with lower value desirable. Attention/memory scores range from 0 - 36 with lower value desirable. Gastrointestinal tract scores range from 0 - 36 with lower value desirable. Urinary scores range from 0 - 36 with lower value desirable. Sexual function scores range from 0 - 24 with lower value desirable. Miscellaneous scores range from 0 - 48 with lower value desirable. Repeated-measure analysis.
| score on a scale | Optimized Medical Treatment | LCIG |
|---|---|---|
| Cardiovascular including falls | -1.84 ± 0.82 | -1.76 ± 0.86 |
| Sleep/fatigue | -7.11 ± 2.02 | -6.06 ± 2.06 |
| Mood/cognition | -5.99 ± 3.06 | -7.84 ± 3.11 |
| Perceptual problems/hallucinations | -1.53 ± 0.70 | -1.14 ± 0.72 |
| Attention/memory | -1.20 ± 1.60 | -2.15 ± 1.66 |
| Gastrointestinal tract | -0.85 ± 1.09 | -3.43 ± 1.14 |
| Urinary | -3.65 ± 1.90 | -4.83 ± 1.96 |
| Sexual function | 0.88 ± 0.86 | 0.10 ± 0.90 |
| Miscellaneous | -3.87 ± 1.53 | -5.16 ± 1.60 |
The PDSS-2 addresses PD-specific sleep disturbances such as restless leg syndrome (RLS), morning akinesia, pain, and sleep apnea. The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 \[never\] to 4 \[very often\]). Scores are calculated for each of the 3 domains (motor symptoms at night, PD symptoms at night, and disturbed sleep) as well as a total score. The PDSS-2 domain scores range from 0 to 20 and the total score is a sum of the 3 domains and ranges from 0 to 60. Repeated measure analysis.
| score on a scale | Optimized Medical Treatment | LCIG |
|---|---|---|
| Motor symptoms at night | -2.21 ± 1.04 | -2.79 ± 1.05 |
| PD symptoms at night | -1.77 ± 0.66 | -1.53 ± 0.69 |
| Disturbed sleep | -4.88 ± 0.74 | -2.89 ± 0.75 |
UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease of 42 total questions. Part I (Questions 1 - 4), Part II (Questions 5 - 17), Part III (Questions 18 - 31), and Part IV (Questions 32 - 42). Questions 35 - 38 and 40 - 42 are 2-point (0 and 1), all other questions are 5-point (0 - 4). Part I is the sum of Questions 1 - 4; scores range from 0 to 16 with lower value desirable. Part III is the sum of Questions 18 - 31 (Questions 20 - 26 apply to multiple body parts, resulting in 27 answers total); scores range from 0 to 108 with lower value desirable. Part IV is the sum of Questions 32 - 42; scores range from 0 to 23 with lower value desirable.
| score on a scale | Optimized Medical Treatment | LCIG |
|---|---|---|
| Part I | 0.20 ± 0.39 | 0.39 ± 0.39 |
| Part III | 1.32 ± 1.84 | -0.89 ± 1.80 |
| Part IV | -0.61 ± 0.53 | -2.31 ± 0.52 |
PAS is a 12-item scale developed specifically to measure severity in anxiety in Parkinson's disease for the following items: Feeling anxious or nervous; Feeling tense or stressed; Being unable to relax; Excessive worrying about everyday matters; Fear of something bad, or even the worst, happening; Panic or intense fear; Shortness of breath; Heart palpitations or heart beating fast; Fear of losing control; Social situations; Public settings; Specific objects or situations. Severity for each item is rated as: 0, Never; 1 Rarely; 2, Sometimes; 3, Often; 4, Nearly always. Total score is the sum of the12 item scores, with a range of 0 to 48; a lower value is desirable.
| score on a scale | Optimized Medical Treatment | LCIG |
|---|---|---|
| Change From Baseline at Week 26 in Parkinson's Anxiety Scale (PAS) Total Score | -0.75 ± 1.28 | -2.29 ± 1.27 |
The GDS-15 is a short, self-report reliable and valid screening instrument for depression in the elderly of 15 yes/no questions: 1) Satisfied with life 2) Dropped many activities and interests 3) Life is empty 4) Often get bored 5) In good spirits most of the time 6) Afraid that something bad is going to happen 7) Feel happy most of the time 8) Often feel helpless 9) Prefer to stay at home, rather than going out and doing things 10) Feel that have more problems with memory than most 11) Think it is wonderful to be alive now 12) Feel worthless 13) Feel full of energy 14) Situation is hopeless 15) Most subjects are better off. Answers of 'yes' to questions 2, 3, 4, 6, 8, 9, 10, 12, 14, 15 are scored 1 point. Answers of 'no' to questions 1, 5, 7, 11, 13 are scored 1 point. The 15 items are summed and scores range from 0 - 15 with lower value desirable.
| score on a scale | Optimized Medical Treatment | LCIG |
|---|---|---|
| Change From Baseline at Week 26 in Geriatric Depression Scale (GDS-15) Score | 0.25 ± 0.40 | 0.17 ± 0.39 |
The KPPS score is a clinical PD-specific pain scale of 14 items addressing the following 7 domains: musculoskeletal pain, chronic pain, fluctuation-related pain, nocturnal pain, orofacial pain, neuropathic pain, radicular pain. Each domain item is scored by severity (0, none to 3, very severe) multiplied by frequency (0, never to 4, all the time) resulting in a subscore of 0 - 12 (with lower value desirable), the sum of the 14 items gives the total score with a range from 0 to 168 with lower value desirable.
| score on a scale | Optimized Medical Treatment | LCIG |
|---|---|---|
| Total score | -11.32 ± 2.83 | -12.46 ± 2.77 |
| Musculoskeletal Pain Score | -1.72 ± 0.63 | -1.79 ± 0.62 |
| Chronic pain score | -0.84 ± 0.54 | -0.77 ± 0.55 |
| Fluctuation related pain score | -3.77 ± 1.30 | -3.14 ± 1.28 |
| Nocturnal pain score | -2.41 ± 1.04 | -2.78 ± 1.01 |
| Orofacial pain score | -0.74 ± 0.41 | -0.87 ± 0.41 |
| Discoloration and edema score | -0.47 ± 0.65 | -2.27 ± 0.65 |
| Radicular pain score | -1.43 ± 0.39 | -1.47 ± 0.39 |
The PGIC is a 7-point response scale. The participant was asked by the Investigator or qualified designee to rate their change in status using the following 7-point scale: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. PGIC score ranges from 1 to 7 with lower score desirable.
| score on a scale | Optimized Medical Treatment | LCIG |
|---|---|---|
| Patient Global Impression of Change (PGIC) Final Score | 4.9 ± 0.25 | 2.5 ± 0.24 |
Collected over All adverse events are reported from the time of randomization until 30 days following last OMT dose, last study visit, discontinuation of study drug administration, removal of the PEG-J tube or Last LCIG Commercial Transition Visit have elapsed. Median duration of follow-up was 191 days for OMT and 565 days for LCIG in the Treatment Period, and was 1366 days for OMT -> LCIG and 1003.5 days for LCIG -> LCIG in the Extension/Transition period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Optimized Medical Treatment (OMT) | 0/44 (0%) | 4/44 (9.1%) | 13/44 (29.5%) |
| LCIG | 0/45 (0%) | 9/43 (20.9%) | 33/43 (76.7%) |
| Extension/Transition OMT->LCIG | 1/10 (10%) | 2/10 (20%) | 6/10 (60%) |
| Extension/Transition LCIG->LCIG | 0/14 (0%) | 1/14 (7.1%) | 4/14 (28.6%) |
| Event | Optimized Medical Treatment (OMT) | LCIG | Extension/Transition OMT->LCIG | Extension/Transition LCIG->LCIG |
|---|---|---|---|---|
| AORTIC VALVE STENOSISCardiac disorders | 0/44 | 0/43 | 1/10 | 0/14 |
| ILEUS PARALYTICGastrointestinal disorders | 0/44 | 0/43 | 1/10 | 0/14 |
| ASTHENIAGeneral disorders | 0/44 | 0/43 | 1/10 | 0/14 |
| DEATHGeneral disorders | 0/44 | 0/43 | 1/10 | 0/14 |
| PERITONITISInfections and infestations | 0/44 | 0/43 | 1/10 | 0/14 |
| PNEUMONIAInfections and infestations | 0/44 | 0/43 | 1/10 | 0/14 |
| SYNCOPENervous system disorders | 0/44 | 0/43 | 1/10 | 0/14 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 0/44 | 0/43 | 1/10 | 0/14 |
| PNEUMONIA ASPIRATIONRespiratory, thoracic and mediastinal disorders | 0/44 | 0/43 | 1/10 | 0/14 |
| ROTATOR CUFF SYNDROMEMusculoskeletal and connective tissue disorders | 0/44 | 0/43 | 0/10 | 1/14 |
| Event | Optimized Medical Treatment (OMT) | LCIG | Extension/Transition OMT->LCIG | Extension/Transition LCIG->LCIG |
|---|---|---|---|---|
| STOMA SITE PAINInjury, poisoning and procedural complications | 0/44 | 6/43 | 3/10 | 1/14 |
| DYSKINESIANervous system disorders | 1/44 | 4/43 | 2/10 | 0/14 |
| FALLInjury, poisoning and procedural complications | 7/44 | 4/43 | 0/10 | 0/14 |
| ABDOMINAL PAINGastrointestinal disorders | 0/44 | 5/43 | 1/10 | 1/14 |
| STOMA SITE INFECTIONInfections and infestations | 0/44 | 5/43 | 1/10 | 0/14 |
| ABDOMINAL DISCOMFORTGastrointestinal disorders | 0/44 | 0/43 | 1/10 | 0/14 |
| ABDOMINAL DISTENSIONGastrointestinal disorders | 0/44 | 2/43 | 1/10 | 0/14 |
| DUODENAL ULCERGastrointestinal disorders | 0/44 | 1/43 | 1/10 | 0/14 |
| DYSPEPSIAGastrointestinal disorders | 0/44 | 0/43 | 1/10 | 0/14 |
| DYSPHAGIAGastrointestinal disorders | 0/44 | 0/43 | 1/10 | 0/14 |
Safety dataset: all participants randomized to OMT, and all participants randomized to LCIG who had study device (NJ and/or PEG-J) placement.
| Age, Continuous(years) | Optimized Medical Treatment | LCIG | Total |
|---|---|---|---|
| Mean | 68.6 ± 6.21 | 66.9 ± 7.34 | 67.8 ± 6.81 |
| Sex: Female, Male(Participants) | Optimized Medical Treatment | LCIG | Total |
|---|---|---|---|
| Female | 20 | 14 | 34 |
| Male | 24 | 29 | 53 |
| Ethnicity (NIH/OMB)(Participants) | Optimized Medical Treatment | LCIG | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 7 | 16 |
| Not Hispanic or Latino | 35 | 36 | 71 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Optimized Medical Treatment | LCIG | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 9 | 8 | 17 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 35 | 34 | 69 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Non-Motor Symptoms Scale (NMSS) Total Score(score on a scale) | Optimized Medical Treatment | LCIG | Total |
|---|---|---|---|
| Mean | 112.4 ± 51.37 | 99.7 ± 46.49 | 106.2 ± 49.14 |
| Modified Parkinson's Disease Sleep Scale (PDSS-2) Total Score(score on a scale) | Optimized Medical Treatment | LCIG | Total |
|---|---|---|---|
| Mean | 30.3 ± 8.55 | 29.9 ± 7.36 | 30.1 ± 7.94 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Oct 2015 to primary completion in May 2020, 54 months.
Results were first posted in Jun 2021, 1 year after primary completion.
Of 39 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 54 months is above that.
Counting every sponsor, half of 67 studies reached it within 35 months; a quarter within 22 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Levodopa · Carbidopa